393 related articles for article (PubMed ID: 16791802)
21. FDG avidity and PET/CT patterns in primary gastric lymphoma.
Radan L; Fischer D; Bar-Shalom R; Dann EJ; Epelbaum R; Haim N; Gaitini D; Israel O
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1424-30. PubMed ID: 18418594
[TBL] [Abstract][Full Text] [Related]
22. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis.
Treglia G; Zucca E; Sadeghi R; Cavalli F; Giovanella L; Ceriani L
Hematol Oncol; 2015 Sep; 33(3):113-24. PubMed ID: 25047160
[TBL] [Abstract][Full Text] [Related]
23. [18F-FDG positron emission tomography in the diagnosis and staging of marginal zone non-Hodgkin lymphomas].
Khodzhibekova MM; Tiutin LA; Kostenikov NA; Il'in NV; Vinogradova IuN
Vestn Rentgenol Radiol; 2015; (1):16-21. PubMed ID: 25864360
[TBL] [Abstract][Full Text] [Related]
24. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
25. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT and primary hepatic MALT: a case series.
Albano D; Giubbini R; Bertagna F
Abdom Radiol (NY); 2016 Oct; 41(10):1956-9. PubMed ID: 27259334
[TBL] [Abstract][Full Text] [Related]
27. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose.
Phongkitkarun S; Varavithya V; Kazama T; Faria SC; Mar MV; Podoloff DA; Macapinlac HA
World J Gastroenterol; 2005 Dec; 11(46):7284-9. PubMed ID: 16437629
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
[TBL] [Abstract][Full Text] [Related]
29. Value of
Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
[TBL] [Abstract][Full Text] [Related]
30. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
32. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type.
Raderer M; Traub T; Formanek M; Virgolini I; Osterreicher C; Fiebiger W; Penz M; Jäger U; Pont J; Chott A; Kurtaran A
Br J Cancer; 2001 Nov; 85(10):1462-6. PubMed ID: 11720429
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary mucosa-associated lymphoid tissue lymphoma: computed tomography and ¹⁸F fluorodeoxyglucose-positron emission tomography/computed tomography imaging findings and follow-up.
Zhang WD; Guan YB; Li CX; Huang XB; Zhang FJ
J Comput Assist Tomogr; 2011; 35(5):608-13. PubMed ID: 21926857
[TBL] [Abstract][Full Text] [Related]
35. Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients.
Mayerhoefer ME; Giraudo C; Senn D; Hartenbach M; Weber M; Rausch I; Kiesewetter B; Herold CJ; Hacker M; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Nucl Med; 2016 Feb; 41(2):101-5. PubMed ID: 26402137
[TBL] [Abstract][Full Text] [Related]
36. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type.
Hoffmann M; Kletter K; Diemling M; Becherer A; Pfeffel F; Petkov V; Chott A; Raderer M
Ann Oncol; 1999 Oct; 10(10):1185-9. PubMed ID: 10586335
[TBL] [Abstract][Full Text] [Related]
37. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
38. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography comparison of gastric lymphoma and gastric carcinoma.
Li XF; Fu Q; Dong YW; Liu JJ; Song XY; Dai D; Zuo C; Xu WG
World J Gastroenterol; 2016 Sep; 22(34):7787-96. PubMed ID: 27678362
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
[TBL] [Abstract][Full Text] [Related]
40. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma.
Hoffmann M; Kletter K; Becherer A; Jäger U; Chott A; Raderer M
Oncology; 2003; 64(4):336-40. PubMed ID: 12759529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
